Premier Alternatives

Pathalys Pharma

Raleigh, NC · Founded 2021 · Privately Held (backing)

Developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseases. Pathalys Pharma is based in Raleigh, NC and was founded in 2021. Its last known valuation is $295 million. It has raised $266 million.

Last price · $/share
—
Implied valuation
$295.0M
Total raised
$266.0M
Last round
—

Pathalys Pharma key facts

  • Developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseases.
  • Pathalys Pharma’s last known valuation is $295.0M.
  • It has raised $266.0M; the latest was Early Stage VC ($105.0M) in Aug 2024.
  • Notable investors include KB Investment, OrbiMed, Samsara BioCapital, The Carlyle Group, Japan Post Investment — 12 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Pathalys Pharma with a free account
  • ·The complete investor list: 12 names
  • ·Watch Pathalys Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Pathalys Pharma funding rounds

No rounds on record

No funding rounds for Pathalys Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Pathalys Pharma valuation

Pathalys Pharma's last known valuation is $295 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

Pathalys Pharma investors

12 investors are on record for Pathalys Pharma, including KB Investment, OrbiMed, Samsara BioCapital and The Carlyle Group. By type, the record holds 2 venture capital firms, 2 private equity firms and 1 hedge fund.

About Pathalys Pharma

Developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseases. The company creates upacicalcet, which is a novel calcimimetic with the potential to improve the treatment of SHPT (secondary hyperparathyroidism) in hemodialysis patients by mimicking the action of calcium on tissues through the activation of the calcium-sensing receptor that is expressed in various human organ tissues, enabling healthcare companies to treat patients with end-stage critical kidney disease.

Sector
Healthcare
HQ
Raleigh, NC, United States
Founded
2021
Employees
8
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$295.0M

Pathalys Pharma’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.